Science and Technology

Author Archive | xchem-editor

October 31, 2017

Consortium of X-Chem, Harvard T.H. Chan School of Public Health and Other Leading Academic Institutions Wins Research Award from the Department of Defense

X-Chem, Inc., a privately held biotechnology company with a proprietary and innovative platform to generate small molecule therapeutics, today announced the award of a DOD CDMRP research grant entitled “Chemigenomic Drug Discovery for Tuberculosis.” The grant was awarded to a research consortium led by Eric Rubin, M.D., Ph.D., Irene Heinz professor of Immunology and Infectious […]

Continue Reading
October 27, 2017

Isoform-Selective ATAD2 Chemical Probe with Novel Chemical Structure and Unusual Mode of Action

October 18, 2017|ACS Chemical Biology|Isoform-Selective ATAD2 Chemical Probe with Novel Chemical Structure and Unusual Mode of Action ATAD2 (ANCCA) is an epigenetic regulator and transcriptional cofactor, whose overexpression has been linked to the progress of various cancer types. Here, we report a DNA-encoded library screen leading to the discovery of BAY-850, a potent and isoform […]

Continue Reading
October 3, 2017

X-Chem further expands Collaboration with Bayer to Discover Novel Medicines

WALTHAM, Mass. – October 3rd, 2017 – X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics based on an industry leading DNA-encoded library containing over 120 billion small molecules, and Bayer have further expanded their drug discovery collaboration across multiple therapeutic […]

Continue Reading
May 16, 2017

X-Chem and Vertex Enter into Multi-Target Genetic Disease Collaboration

[Download PDF] X-Chem and Vertex Enter into Multi-Target Genetic Disease Collaboration – Agreement will enable discovery of small-molecule leads against validated targets for severe, genetic diseases – X-Chem to receive upfront payment and potential research, development and regulatory milestones and licensing fees, plus additional royalties on future sales WALTHAM, Mass. – May 15, 2017 – […]

Continue Reading
April 26, 2017

X-Chem Announces Publication in Nature

WALTHAM, Mass. –April 26, 2017 – X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative DNA-encoded library platform (DEXTM) to the discovery of the next generation of small molecule therapeutics, announced today a publication in Nature. The article, co-authored by scientists from AstraZeneca Inc. and Heptares, Inc., describes the crystal structure of protease-activated […]

Continue Reading
April 26, 2017

Structural insight into allosteric modulation of protease-activated receptor 2

April 26, 2017|Nature|Structural insight into allosteric modulation of protease-activated receptor 2 Protease-activated receptors (PARs) are a family of G-protein-coupled receptors (GPCRs) that are irreversibly activated by proteolytic cleavage of the N terminus, which unmasks a tethered peptide ligand that binds and activates the transmembrane receptor domain, eliciting a cellular cascade in response to inflammatory signals […]

Continue Reading
March 21, 2017

X-Chem and Ono Enter into Multi-Target Drug Discovery Collaboration

WALTHAM, Mass. – March 21, 2017 – X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, today announced a partnership with Ono Pharmaceutical Co., Ltd. (Ono). Under the terms of the agreement X-Chem will apply its proprietary DEXTM libraries, which contain over […]

Continue Reading
March 20, 2017

X-Chem Announces Strategic Collaboration with Astellas Pharma Across Multiple Therapeutic Areas

WALTHAM, Mass. – March 20 2017 – X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, announced the signing of a broad drug discovery collaboration with Astellas Pharma Inc. (Astellas). The collaboration will enable the discovery of novel lead compounds for complex […]

Continue Reading
February 15, 2017

X-Chem Expands Collaboration with Janssen in Inflammatory Diseases

WALTHAM, Mass. – February 15, 2017 – X-Chem, Inc. (X-Chem) announced today that it has expanded its collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover new drug leads for the treatment of inflammatory disease. The multi-target expansion builds on the parties’ existing discovery and license partnership, […]

Continue Reading
January 5, 2017

Discovery of a potent BTK inhibitor with a novel binding mode using parallel selections with a DNA-encoded chemical library.

2017 Jan. 5|Chembiochem.|Discovery of a potent BTK inhibitor with a novel binding mode using parallel selections with a DNA-encoded chemical library. We have identified and characterized novel potent inhibitors of Bruton’s tyrosine kinase (BTK) from a single DNA encoded library of over 110 million compounds using multiple parallel selection conditions…Analysis of the co-crystal structure of […]

Continue Reading